secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K/A
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001641172-25-019884
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake
--------------------------------------------------------------------------------

- Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.
- Royalty on US net sales: 12% up to $65M revenue, 15% above; minimum 80,000 tubes/year penalty clause.
- Sellers receive preferred stock convertible to 10% of fully diluted Biofrontera Inc. common equity.
- Sellers get 1-2 board seats as long as they hold preferred stock; term sheet void if conditions unmet.
- Buyer assumes all US supply costs and legal defense; stockholder vote required for conversion rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225019884/0001641172-25-019884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000164117225019884/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-019884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer